Orphazyme A/S (ORPH) shares were falling -10.33% to trade at $0.7575 in pre-market at last check. Orphazyme (ORPH) stock lost -4.00% to close Monday’s session at $0.84. The stock volume remained 1.06 million shares, which was lower than the average daily volume of 1.52 million shares within the past 50 days.
Orphazyme (ORPH) shares have fallen by -93.39% over the last 12 months, and they have moved up by 37.25% in the past week. Over the past three months, the stock has lost -69.83%, while over the past six months, it has shed -80.53%. Further, the company has a current market of $30.62 million and its outstanding shares stood at 34.90 million. ORPH stock is falling following a delisting initiative.
What choice does ORPH stock have made?
Orphazyme (ORPH) is a late-stage biopharmaceutical organization creating arimoclomol for Niemann-Pick infection type C (NPC). ORPH is settled in Denmark and has tasks in the U.S. what’s more Switzerland. ADSs addressing ORPH’s portions are recorded on Nasdaq U.S. (ORPH) and its portions are recorded on Nasdaq Copenhagen (ORPHA).
Orphazyme (ORPH) reports that following the choice to deliberately delist the Company’s American Depositary Shares (“ADSs”) addressing its standard offers from Nasdaq Global Select Market (“Nasdaq Global”), the Company has today started the delisting and recorded a Form 25 with the Securities and Exchange Commission (“SEC”).
- The delisting is relied upon to become powerful on March 31, 2022.
- ORPH has likewise documented present viable revisions on two Registration Statements on Form S-8 and one Registration Statement on Form F-3 recently recorded by the Company with the SEC to eliminate from enrollment any unsold protections recently enlisted consequently.
- Following the delisting of the Company’s ADSs from Nasdaq Global, ORPH expects to document a Form 15 with the SEC to suspend it’s detailing commitments under the Securities Exchange Act of 1934, as revised.
- ORPH expects that the de-registration of the ADSs and the underlying common shares will become viable 90 days after the recording of Form 25 with the SEC.
ORPH going through rebuilding
Orphazyme (ORPH) last week reported that following the Company’s documenting of a request for an in-court rebuilding (in Danish rekonstruktion) of Orphazyme on March 10, 2022, the Danish Maritime and Commercial High Court (the “Court”) has initiated the rebuilding procedures of the Company on March 11, 2022, at 7:00 am (CET). The Court has designated lawyer John Sommer Schmidt as rebuilding manager for ORPH.